BioHarvest Sciences (BHST) Stock Overview
Operates as a biotechnology company in Israel and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BHST Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BioHarvest Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.80 |
| 52 Week High | US$12.80 |
| 52 Week Low | US$1.80 |
| Beta | 1.35 |
| 1 Month Change | -14.29% |
| 3 Month Change | -43.75% |
| 1 Year Change | -75.68% |
| 3 Year Change | -60.44% |
| 5 Year Change | -81.95% |
| Change since IPO | -79.55% |
Recent News & Updates
BHST: CDMO Contract Shift Will Drive Long-Term Revenue From 2027
Analysts have reduced their fair value estimate for BioHarvest Sciences from $13.67 to $10.50. Recent research cites lower price targets tied to Q2 revenue shortfalls, reduced near-term guidance, and a shift in focus toward CDMO contracts that are expected to contribute more meaningfully from 2027.BioHarvest Sciences Inc. (NASDAQ:BHST) Just Reported And Analysts Have Been Cutting Their Estimates
BioHarvest Sciences Inc. ( NASDAQ:BHST ) missed earnings with its latest second-quarter results, disappointing...
BHST: Data Science Grant Will Support Future R&D Productivity Upside
Analysts have reduced their fair value estimate for BioHarvest Sciences from $10.00 to $5.00. They cite updated assumptions that now reflect a higher discount rate, lower projected revenue growth, slightly softer profit margins, and a modestly adjusted future P/E multiple.Recent updates
BHST: CDMO Contract Shift Will Drive Long-Term Revenue From 2027
Analysts have reduced their fair value estimate for BioHarvest Sciences from $13.67 to $10.50. Recent research cites lower price targets tied to Q2 revenue shortfalls, reduced near-term guidance, and a shift in focus toward CDMO contracts that are expected to contribute more meaningfully from 2027.BioHarvest Sciences Inc. (NASDAQ:BHST) Just Reported And Analysts Have Been Cutting Their Estimates
BioHarvest Sciences Inc. ( NASDAQ:BHST ) missed earnings with its latest second-quarter results, disappointing...BHST: Data Science Grant Will Support Future R&D Productivity Upside
Analysts have reduced their fair value estimate for BioHarvest Sciences from $10.00 to $5.00. They cite updated assumptions that now reflect a higher discount rate, lower projected revenue growth, slightly softer profit margins, and a modestly adjusted future P/E multiple.CDMO Pipeline And Capacity Expansion Will Face Setbacks Yet Ultimately Support Future Earnings
Catalysts About BioHarvest Sciences BioHarvest Sciences develops and commercializes plant derived compounds using its patented Botanical Synthesis platform, serving pharmaceuticals, nutraceuticals, cosmetics and nutrition. What are the underlying business or industry changes driving this perspective?
CDMO Pipeline And Hydration Expansion Will Transform Long Term Earnings Power
Catalysts About BioHarvest Sciences BioHarvest Sciences uses its patented Botanical Synthesis platform to produce consistent, highly potent plant based compounds for branded nutraceutical products and contract development and manufacturing services. What are the underlying business or industry changes driving this perspective?BioHarvest Earnings: Strong Revenue Growth And Expanding VINIA Opportunities
Summary BioHarvest Sciences delivered strong 3Q25 results with 39% YoY revenue growth, improved gross margins, and a robust cash position post equity raise. VINIA remains the core growth driver, with expansion into U.S. hydration and athlete supplement markets expected to fuel further revenue gains in 2026. BHST is nearing adjusted EBITDA breakeven, supported by a strengthened balance sheet and new product launches, though ongoing cash burn and dilution risk remain. Despite a premium valuation, the recent stock pullback presents a buying opportunity, with upside potential tied to VINIA growth and CDMO business expansion. Read the full article on Seeking AlphaWith BioHarvest Sciences Inc. (NASDAQ:BHST) It Looks Like You'll Get What You Pay For
BioHarvest Sciences Inc.'s ( NASDAQ:BHST ) price-to-sales (or "P/S") ratio of 5.1x may look like a poor investment...Here's Why BioHarvest Sciences (NASDAQ:BHST) Can Afford Some Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...BioHarvest Sciences Inc. (NASDAQ:BHST) Not Flying Under The Radar
When you see that almost half of the companies in the Personal Products industry in the United States have...Shareholder Returns
| BHST | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -5.3% | -4.6% | -0.2% |
| 1Y | -75.7% | -4.9% | 14.8% |
Return vs Industry: BHST underperformed the US Personal Products industry which returned -5% over the past year.
Return vs Market: BHST underperformed the US Market which returned 15.5% over the past year.
Price Volatility
| BHST volatility | |
|---|---|
| BHST Average Weekly Movement | 10.2% |
| Personal Products Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BHST has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BHST's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 89 | Zaki Rakib | www.bioharvest.com |
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients.
BioHarvest Sciences Inc. Fundamentals Summary
| BHST fundamental statistics | |
|---|---|
| Market cap | US$41.03m |
| Earnings (TTM) | -US$11.07m |
| Revenue (TTM) | US$35.48m |
Is BHST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BHST income statement (TTM) | |
|---|---|
| Revenue | US$35.48m |
| Cost of Revenue | US$14.56m |
| Gross Profit | US$20.91m |
| Other Expenses | US$31.99m |
| Earnings | -US$11.07m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 58.95% |
| Net Profit Margin | -31.21% |
| Debt/Equity Ratio | 13.5% |
How did BHST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 02:26 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioHarvest Sciences Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Amit Dayal | H.C. Wainwright & Co. |
| Anthony Vendetti | Maxim Group |